Methods for manufacturing drug delivery systems are provided. The drug delivery systems may include a substrate coated with at least one polymer and at least one active compound. The substrate may include yarns, yarn precursors, threads, filaments, fibers, and/or other suitable substrates. The methods may include applying a solution including a monomer and an active compound on the substrate. The methods may also include exposing the solution and the substrate to UV light to initiate polymerization of the solution. The substrate is further configured into a reversibly removable patch or section to deliver active compounds to a user. The garments, patches, and sections are configured to provide an amount of active even after repeated uses, wears, applications, and/or launderings and further provide for replacement.

The device, that can be implanted in the intestinal cavity, comprises a reactor comprising a semi-permeable or porous membrane or coating linked to a element for attachment to an intestinal or gastric wall. The reactor can be in the form of a ribbon, a structure having more than two faces or an open structure delimiting a lumen, comprising, or formed from, a semi-permeable or porous membrane. The reactor can also delimit, at least partially with the semi-permeable or porous membrane of same, a closed inner space. The reactor can comprise or carry enzymes or micro-organisms, in particular bacteria or yeast. The reactor is used for generating a chemical reaction with one or more molecules present in the intestine, or for producing one or more biologically active molecules. It can, in particular, be used for consuming sugars, disaccharides and simple sugars or producing essential amino acids or other molecules having a positive effect on the health.

A flexible anchor for coupling a suture to a bone is provided. The anchor is composed of non-woven electrospun fibers and has an elongate tubular body that extends from a first end to a second end. The anchor is configured to receive a suture that enters the anchor through a first aperture and exits the anchor through a second aperture. When free ends of the suture are pulled, the anchor transitions from a first configuration to a second anchoring configuration.

Disclosed are conjugates between stanozolol and hyaluronic acid or a hyaluronic acid salt, characterised in that stanozolol is conjugated with the carboxyl group of hyaluronic acid or the hyaluronic acid salt via a spacer that forms an ester bond with the hydroxyl group of stanozolol and an ester or amide bond with the carboxyl group of hyaluronic acid or the hyaluronic acid salt. The conjugates according to the invention are useful to prepare hydrogels, injectable hydrogels, hydrogels for external use, creams, lotions, foams, aqueous solutions for intra-articular use, emulsions for ophthalmic use, eyedrops, scaffolds, artificial tissues and culture media.

The invention relates to a method for coating the balloon of a balloon catheter, wherein the surface of the balloon is wetted at least partially with a first solution containing a polysaccharide and the part of the surface of the balloon wetted with the first solution is wetted with a second solution containing an active agent. In this way, the balloon is provided with an active agent layer which is effectively applied to the inner wall of the vessel when the balloon is inflated and moreover results in a delayed long-lasting release of the active agent.

Compositions comprising electrospun fibers and pharmaceutical agents encapsulated thereto are provided. Further, articles such as medical devices and methods of use of said fibers, including, but not limited to coating of medical tubes, are provided.

Devices and methods for treating ischemia and reperfusion injury (IRI) are configured for sustained-release of anti-proliferative drug into the wall of a blood vessel (to prevent in-stent stenosis), and for sustained-release of leptin antagonist into the lumen to be carried by the blood and be uptaken by tissue cells that were subjected to IRI.

Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent. The present hyaluronic acid-based compositions have enhanced flow characteristics, hardness, and persistence compared to known hyaluronic acid-based compositions. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.

Drug-eluting polymer coatings for biomedical implants are disclosed, as well as assemblies and kits containing same. The polymer coatings are deposited on the biomedical implants via a solvent-free, chemical vapor deposition process. The polymer coatings exhibit controlled release of the drug with substantially no burst release and substantially linear release over time. Also disclosed are methods of making and using the coatings, assemblies, and kits.

A non-synthetic, hydrophilic, biodegradable, biocompatible polysaccharide based non-toxic anti-adhesion hydrogel barrier is disclosed herein. The barrier of the present invention is formed by constructing a unique interpenetrating, crosslinked network with a unique porosity. Furthermore, the barrier of the present invention is comprised of tunable biopolymers for controllable mechanical robustness and degradation. The barrier of the present invention effectively reduces unwanted adhesions using non-synthetic components.